Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 13/20 | 0.74 |
| ▸ | ATF1 | P18846 | 12/20 | 0.74 |
| ▸ | XPO1 | O14980 | 4/20 | 0.72 |
| ▸ | JUN | P05412 | 2/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.63 |
| ▸ | RELA | Q04206 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077675 | 0.86 | XPO1 (0.69) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL458841 | 0.78 | NFKB1 (1.00) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL13015082 | 0.76 | EPHX1 (0.54) | NFKB1ATF1XPO1NPC1RAB9A | |
| SCHEMBL1864557 | 0.76 | NFKB1 (0.78) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL4967913 | 0.76 | ABL1 (0.64) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL4970130 | 0.75 | ABL1 (0.67) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL1499586 | 0.74 | MAPT (0.61) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL1666251 | 0.74 | NPC1 (0.65) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL473934 | 0.74 | ATF1 (0.62) | NFKB1ATF1XPO1JUNNFKB2 | |
| SCHEMBL13077672 | 0.74 | XPO1 (0.71) | NFKB1ATF1XPO1JUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080194607-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188491-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 2156/4885ATF1 2969/4885XPO1 1613/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 2117/4885ATF1 2956/4885XPO1 1607/4885 |
| US-20080214635-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 2117/4885ATF1 2956/4885XPO1 1607/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 2117/4885ATF1 2956/4885XPO1 1607/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | NFKB1 2129/4885ATF1 2975/4885XPO1 1583/4885 |
| US-20080188491-A1 | Modulation of pathogenicity | NR4A1, MSR1, NR4A2 | NFKB1 1795/4885ATF1 2793/4885XPO1 1861/4885 |
| US-20080194607-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 2117/4885ATF1 2956/4885XPO1 1607/4885 |
| US-20080188536-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 2117/4885ATF1 2956/4885XPO1 1607/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | NFKB1 1972/4885ATF1 2706/4885XPO1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.